Low urgency

Azodicarbonamide (ADA); Request for Information

Detected July 5, 2026 · in Dietary-Supplement Labeling (FDA)

FDA requests information on azodicarbonamide (ADA) uses and safety in human food and as a food contact substance. This may affect dietary supplement manufacturers using ADA in packaging or processing.

Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 5, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers using ADA in food contact materials or processing aids. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments due by July 13, 2026 (60 days after publication on May 13, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA issued a Request for Information (RFI) on ADA, signaling potential future regulatory action (e.g., ban or restrictions).

Who it affects

Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers using ADA in food contact materials or processing aids.

What you must do

Submit comments or data to FDA by the deadline if your business uses ADA.

Deadline

Comments due by July 13, 2026 (60 days after publication on May 13, 2026).

Source: https://www.federalregister.gov/documents/2026/05/13/2026-09508/azodicarbonamide-ada-request-for-information

Never miss a change like this again

Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Dietary-Supplement Labeling (FDA)